The Issues with Risk and Benefit Evaluation for Invasive Treatment of Cardiac Disease

Ann Thorac Surg. 2021 Dec;112(6):1733-1735. doi: 10.1016/j.athoracsur.2021.05.041. Epub 2021 Jun 8.

Authors

Torsten Doenst¹, Volkmar Falk², Mario Gaudino³

Affiliations

¹ Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich-Schiller-University of Jena, Jena, Germany. Electronic address: doenst@med.uni-jena.de.
² Department of Cardiovascular Surgery, Charite University Hospital, Berlin, Germany; Department of Cardiothoracic and Vascular Surgery, German Heartcenter Berlin, Berlin, Germany.
³ Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.

PMID: 34111384
DOI: 10.1016/j.athoracsur.2021.05.041

No abstract available

Publication types

Editorial

MeSH terms

Decision Making*
Europe / epidemiology
Heart Diseases / surgery*
Humans
Morbidity / trends
Myocardial Revascularization / methods*
Postoperative Complications / epidemiology*
Risk Assessment / methods*
Societies, Medical*